Business Wire

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

14.9.2023 11:10:00 EEST | Business Wire | Press release

Share

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi). This validation underlines the company’s commitment to aligning its efforts to tackle climate change and reduce global warming in line with the 2015 Paris Agreement. The SBTi drives ambitious climate action in the private sector, by enabling organizations to set science-based emissions reduction targets, while maximizing transparency, accountability, and corporate leadership through annual disclosure and progress against the targets.

“Driving environmental stewardship to decarbonize our business operations, both within and beyond the factory gates, has been a long-time priority at Boehringer Ingelheim,” said Felix Gutsche, Boehringer Ingelheim’s Head of Corporate Strategy & Consulting. “Having our emissions reduction targets approved by a respected organization like SBTi confirms that our efforts align with the current global agenda.”

In 2021 Boehringer Ingelheim committed reducing absolute scope 1 and 2 GHG emissions1 by 58.9 percent and absolute scope 3 GHG emissions2 by 27.5 percent (from a 2019 base year). The recent SBTi verification underscores Boehringer Ingelheim’s ongoing efforts.

The company recently added its production sites Fornovo (Italy) and Paulínia (Brazil) to its list of carbon-neutral certified sites, bringing the total to seven worldwide. This achievement resulted amongst others from the purchase and installation of renewable energy solutions, as well as ambitious carbon reduction measures. At other sites, including Dortmund and Katharinenhof (Germany), Gainesville (USA), Sant Cugat (Spain), and Zhangjian (China) the company initiated the integration of circular economy principles into development and manufacturing processes, green mobility concepts, as well as sustainability building standards, e.g., Leadership in Energy and Environmental Design (LEED) certification for office buildings.

Boehringer Ingelheim’s efforts to implement its low-carbon transformation are driven through the MORE GREEN pillar within its Sustainable Development - For Generations program. To foster low-carbon technologies and solutions, Boehringer Ingelheim applies an internal carbon price of EUR 100 per ton CO2 emissions for investments, which has been fully established at all sites. The company also emphasizes environmental sustainability in larger projects, providing another EUR 130 million for projects that contribute to the global MORE GREEN goals. This fund has now initiated over 60 new environmental sustainability projects since 2020.

To support certified climate contribution projects that help mitigate the environmental impact of currently unavoidable emissions, Boehringer Ingelheim continues to partner with ClimateSeed. This reputable social enterprise offers a broad portfolio of internationally recognized Verified Emissions Reduction projects that not only safeguard biodiversity and ecosystem services, but also benefit local communities.

Click here for the full release: https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-green/boehringer-receives-sbti-validation-co2-reduction

References:
1Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
2Scope 3 GHG emissions are emissions from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution and use of sold products.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Harro Ten Wolde
Head of Global Media Relations
Email: harro.ten_wolde@boehringer-ingelheim.com
Phone Number: +49 (6132) 77-181352

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye